FTH

7.9408.63%
CW

Christopher W. Gerry

General Counsel & Secretary

Mr. Christopher W. Gerry, J.D., was President at Faeth Therapeutics, Inc. (formerly known as Sensei Biotherapeutics, Inc.) from November 14, 2025 until June 12, 2026, served as Director since February 13, 2026 until June 12, 2026 and serves as its Secretary and serves as its General Counsel from July 2022 and served as Senior Vice President since 2024 until November 2025 and served as its Vice President until 2024 and served as its Vice President from July 2022. He is a life sciences attorney with experience in operations, business development and strategy. Prior to joining Sensei in July 2022, he served as VP, Deputy General Counsel at AVROBIO, where he was responsible for SEC reporting and public company affairs, financings, corporate governance, business development and various other legal matters. Previously, he was an associate at Cooley LLP, where he represented life sciences companies in a wide variety of matters through all stages of their life cycle, from initial formation through venture financings, initial public offerings, follow-on offerings and exit events. He holds a B.A. from Dickinson College and earned his J.D. from Boston University School of Law.

Positions